Compare Regeneron Pharmaceuticals Inc (REGN) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Toyota Motor Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Toyota Motor Corp trades at $180.04 (market cap $214.57B). The key difference: Toyota Motor Corp is far larger — about 3× Regeneron Pharmaceuticals Inc's market cap, and Toyota Motor Corp pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| REGN | TM | |
|---|---|---|
Market Cap | $70.79B | $214.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $812.27 | $248.29 |
52-Week Low | $545.46 | $166.50 |
Enterprise Value | $64.74B | $378.04B |
Dividend Yield | 0.56% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Toyota Motor (TM) trades at $180.34, up 1.54% today, showing strong fundamental metrics with a P/E of 9.78 and consistent earnings beats. Technical indicators are neutral overall, with the stock near resistance at $182. Recent news highlights a $3.6 billion Texas plant expansion to shift Tacoma production from Mexico, signaling strategic US investment.
The outlook is positive given undervaluation signals and hybrid vehicle leadership, but risks include margin pressure from rising costs and competitive auto market dynamics. Analyst consensus is mixed with 37.5% buy ratings, suggesting cautious optimism amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
